A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 5
- Registration Number
- NCT01571648
- Locations
- 🇯🇵
Celgene Trial Site, Tokyo, Japan
Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
- Conditions
- Beta Thalassemia MajorBeta Thalassemia Intermedia
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 46
- Registration Number
- NCT01571635
- Locations
- 🇫🇷
Hopital Henri Mondor, Créteil, France
🇬🇷Laiko General Hospital, Ampelokipi - Athens, Greece
🇬🇷Local Institution - 300, Ampelokipi - Athens, Greece
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT01568294
- Locations
- 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital, Tyuuou, Tokyo, Japan
🇯🇵Niigata Cancer Center Hospital, Niigata, Japan
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 216
- Registration Number
- NCT01566695
- Locations
- 🇺🇸
Local Institution - 942, New Haven, Connecticut, United States
🇺🇸Local Institution - 917, Portland, Oregon, United States
🇺🇸Local Institution - 924, Houston, Texas, United States
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
- Conditions
- Scleroderma, SystemicInterstitial Lung DiseaseSclerosis, SystemicSystemic SclerosisSystemic Scleroderma
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 23
- Registration Number
- NCT01559129
- Locations
- 🇦🇺
Monash Medical Centre, Clayton, Victoria, Australia
🇵🇱SPSK Nr 7 Slaskiego Uniwersytetu Medycznego, Oddzial Chorob Wewnetrznych i Reumatologii, Katowice, Poland
🇵🇱Instytut Reumatologii, Klinika i Poliklinika Ukladowych Chorób Tkanki Lacznej, Warszawa, Poland
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 76
- Registration Number
- NCT01545947
- Locations
- 🇺🇸
NYU School of Medicine, New York, New York, United States
🇺🇸Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT01522547
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine
- Conditions
- Leukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 34
- Registration Number
- NCT01519011
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Moores UCSD Cancer Center MC-0987, La Jolla, California, United States
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 34
- Registration Number
- NCT01497093
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
- Conditions
- Urinary Bladder NeoplasmsCarcinoma, Transitional CellOvarian NeoplasmsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalTumor Virus Infections
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 169
- Registration Number
- NCT01478685
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States